Karolinska Institutet Implements Whole Genome Sequencing to Diagnose Thousands of Rare Disease Patients

Karolinska Institutet study reveals whole genome sequencing integrated into routine care diagnosed 23% of 15,000 rare disease patients.

By: AXL Media

Published: Mar 30, 2026, 10:30 AM EDT

Source: Information for this report was sourced from Karolinska Institutet

A Transformative Model for Genomic Medicine

The diagnostic landscape for rare diseases has undergone a fundamental shift in Sweden through a collaborative effort between academic researchers and clinical practitioners. Over the last ten years, Karolinska University Hospital and SciLifeLab have developed a robust model that integrates whole genome sequencing (WGS) into the standard evaluation of patients with suspected rare disorders. This approach moves beyond traditional testing by analyzing an individual's entire genetic makeup simultaneously, providing a level of detail previously unattainable in routine medicine. The success of the program relies on a multidisciplinary framework where genomic data is interpreted alongside specific clinical observations.

Uncovering the Complexity of Rare Genetic Variants

Data from 15,644 individuals analyzed in the study revealed that genetic causes could be pinpointed for 3,538 patients. These diagnoses involved mutations across more than 1,500 different genes, reflecting the immense biological diversity of rare diseases. Anna Lindstrand, a senior consultant at Karolinska University Hospital, emphasized that WGS allows clinicians to detect subtle genetic alterations that would remain invisible under conventional testing methods. For many families, this genetic "map" provides the first definitive explanation for conditions that have often baffled specialists for years.

Impact on Pediatric Care and Targeted Interventions

A significant majority of the patients benefited by this genomic shift are children, many of whom suffer from severe epilepsies or congenital metabolic disorders. In several critical cases, the identification of a specific genetic variant allowed doctors to offer targeted therapies that prevented permanent disability or early death. Anna Wedell, Director of the Precision Medicine Center Karolinska, noted that the speed and accuracy of these diagnoses are transformative, particularly when early intervention is the only way to alter the course of a life-threatening illness.